A strategic guide for Canadian employers to manage specialty drug costs, high-cost biologics, catastrophic drug claims and group benefits plan sustainability—while protecting employee access to clinically appropriate treatment

Executive Summary

Prescription drug benefits are among the most important—and increasingly complex—components of Canadian employer-sponsored health plans.

For many employers, traditional drug plan management focused on relatively predictable expenses.

Employees filled prescriptions.

Insurers or administrators processed claims.

Employers reviewed utilization and negotiated renewal pricing.

That approach becomes more challenging when a small number of employees or dependants require medications costing tens of thousands of dollars annually, and in some cases substantially more.

Specialty medications, biologic therapies and treatments for complex or rare conditions can create significant financial exposure.

A single high-cost claim may influence an employer’s group benefits renewal, particularly when the claim is not fully protected by an applicable pooling arrangement.

For an Administrative Services Only (ASO) plan, high-cost claims may affect the employer’s cash flow directly, subject to the terms of any stop-loss protection.

But the challenge extends beyond individual catastrophic claims.

Recurring specialty drug therapies may create multiyear financial commitments.

New treatments may change expected utilization.

Drug pricing arrangements can be difficult to understand.

And the relationship between private insurance, provincial drug programs, manufacturer support and pharmacy distribution can introduce administrative complexity.

Employers therefore need a more sophisticated approach.

Effective specialty drug cost management is not simply about restricting expensive medications. It is about ensuring appropriate access, understanding financial exposure and using the available clinical, contractual and purchasing mechanisms responsibly.

A comprehensive strategy should address:

• Specialty drug claims analytics
• Drug plan design and coverage policies
• Evidence-based prior authorization
• Biosimilar utilization
• Specialty pharmacy arrangements
• Drug pricing and compensation transparency
• Public and private drug plan coordination
• High-cost drug pooling
• ASO stop-loss insurance
• Insurer contract provisions
• Employee navigation and support
• Multiyear financial forecasting
• Benefits advisor accountability

Consider an illustrative Canadian employer with 1,000 employees and annual group benefits premiums of $4,000 per employee.

Its total annual group benefits investment is:

1,000 × $4,000 = $4,000,000

These are modeling assumptions, not verified Canadian market averages.

Suppose the employer’s annual prescription drug claims total $1.2 million.

If three new specialty drug claimants each generate $75,000 in annual eligible claims, the combined gross annual cost would be:

3 × $75,000 = $225,000

That amount represents 18.75% of the illustrative existing annual drug claims budget.

However, the employer’s actual financial exposure could be substantially different depending on insurer pooling, plan provisions, public drug program coordination, manufacturer arrangements and applicable risk protection.

The important point is not that every high-cost drug claim will result in a proportionate premium increase.

It is that employers must understand how claims are funded, managed and reflected in future pricing.

This guide explains how Canadian employers can develop a responsible, evidence-based specialty drug management strategy that balances financial sustainability with employee health and access to treatment.

Why Specialty Drugs Are Changing Group Benefits Economics

Traditional drug claims experience can often be analyzed through changes in claim frequency, average prescription cost and utilization.

Specialty drug claims introduce additional considerations.

These medications may involve:

• Complex manufacturing processes
• Biologic therapies
• Specialized handling or administration
• High annual treatment costs
• Long-term or recurring therapy
• Smaller patient populations
• Specialized clinical monitoring

The term specialty drug does not have one universally applied definition across Canadian insurers, pharmacy benefit managers and other stakeholders.

An employer should understand how its own insurer or administrator classifies these medications.

The Financial Challenge

Specialty drug exposure can be concentrated among a relatively small number of claimants.

This creates three important risks.

Claims concentration: A small number of high-cost claims may account for a material share of spending.

Claims persistence: Some therapies continue for multiple years.

Pricing uncertainty: New therapies, changes in treatment patterns and evolving reimbursement arrangements can affect future costs.

The objective is not to discourage appropriate treatment.

It is to manage these risks using reliable evidence and appropriate financial protection.

Understanding Specialty Drugs, Biologics and High-Cost Claims

Not every expensive prescription is a specialty drug.

And not every specialty drug claim qualifies for pooling or stop-loss reimbursement.

Employers should distinguish the underlying concepts.

Key Terminology

These terms should be applied consistently in employer reporting.

Why Definitions Matter

A $60,000 annual drug claim may be financially significant.

But whether it is pooled, insured, reimbursed or retained depends on the applicable contract.

Employers should not assume that a claim becomes fully protected simply because it is expensive.

Establish a Specialty Drug Claims Baseline

A sound mitigation strategy begins with understanding current spending.

The broker or insurer should provide aggregate reporting that identifies material drug cost drivers while respecting employee privacy.

Recommended Drug Claims Dashboard

Using group benefits claims analytics allows employers to distinguish between different sources of cost pressure.

Normalize the Analysis

Claims should be evaluated in the context of:

• Covered employee and dependant counts
• Changes in eligibility
• Plan design
• Workforce composition
• Reporting periods
• Claims submission patterns
• Public program coordination

An increase in total drug spending does not necessarily indicate deteriorating plan performance.

It may reflect workforce growth, improved access to treatment or changes in underlying clinical needs.

Identify the Difference Between Frequency, Severity and Concentration

A useful drug claims review separates three drivers.

Frequency: How often claims occur.

Severity: How much individual claims cost.

Concentration: How much spending is attributable to a relatively small group of claims.

Illustrative Claims Analysis

All figures are hypothetical.

Total spending increased by 12%, reflecting both more claims and a higher average cost.

But the analysis remains incomplete.

The broker should investigate whether the increase is broadly distributed or concentrated in a small number of expensive treatments.

Questions Employers Should Ask

• How much of the increase is attributable to high-cost therapies?
• How much reflects routine prescription utilization?
• Are changes driven by new claimants or existing therapies?
• Are high-cost claims expected to recur?
• What portion is retained by the employer under the current funding arrangement?

These questions are more useful than focusing exclusively on the headline drug trend.

Understand the Financial Impact of Recurring High-Cost Claims

A one-time high-cost claim and a recurring annual treatment can create very different financial implications.

Some therapies may be required for extended periods.

Others may have defined treatment courses.

Employers should avoid assuming that all high-cost claims continue indefinitely.

Illustrative Multiyear Scenario

Assume an employer has one recurring eligible drug claim costing $100,000 annually.

This simplified scenario assumes constant costs, uninterrupted therapy and no offsets.

It does not represent the employer’s net retained cost.

Actual treatment duration, pricing, insurance recoveries and other factors may differ.

The Strategic Implication

Employers should evaluate both annual claims volatility and the possibility of persistent high-cost exposure.

That requires a multiyear perspective.

Evaluate Drug Plan Design Before Making Restrictions

Plan design is an important tool for managing prescription drug costs.

But it should be evaluated carefully.

Potential mechanisms include:

• Formularies
• Generic substitution
• Biosimilar policies
• Prior authorization
• Step therapy where clinically appropriate
• Dispensing limits
• Pharmacy management arrangements
• Coverage coordination
• Drug maximums and other contractual provisions

The appropriate design depends on the insurer, workforce, clinical context and applicable legal requirements.

Plan Design Evaluation Framework

Aligning benefits plan design with business objectives means evaluating financial outcomes alongside access, employee experience and risk.

The Wrong Approach

An employer should not automatically impose a restrictive drug maximum because a high-cost claim has emerged.

Such changes may create employee hardship, contractual concerns and reputational risk.

Any proposed restrictions should receive appropriate actuarial, clinical and legal review.

Biosimilar Strategies: Where Cost Optimization May Be Possible

Biosimilars are an important component of biologic drug management.

Health Canada authorizes biosimilars through a regulatory process assessing their similarity to the reference biologic.

However, the decision to initiate or transition treatment should follow applicable clinical, regulatory and plan requirements.

Employer Questions

• Which biologic therapies have authorized biosimilar alternatives?
• What policies does our insurer apply?
• Are clinical exceptions available?
• How are employees and prescribers informed?
• What transition support is provided?
• What are the expected net financial implications?
• How will outcomes and complaints be monitored?

Illustrative Biosimilar Financial Model

Assume a group of eligible therapies currently generates $400,000 in annual gross claims.

A proposed biosimilar policy is projected to reduce the relevant gross cost by 25%.

Illustrative reduction:

$400,000 × 25% = $100,000

Illustrative revised cost:

$300,000

This is a hypothetical calculation, not a market savings estimate.

Actual savings depend on drug selection, pricing, clinical exceptions, utilization, existing arrangements and applicable public program rules.

The employer should also determine whether lower gross claims translate into lower net plan costs or future premiums.

Prior Authorization: Managing Appropriateness Without Delaying Care

Prior authorization is commonly used to determine whether a medication meets specified coverage criteria.

For high-cost therapies, it can help establish that the claim satisfies the plan’s rules.

But poorly administered authorization processes can create delays and frustration.

Questions to Ask Your Insurer

• Which medications require authorization?
• What clinical criteria apply?
• Who reviews requests?
• How quickly are decisions made?
• What happens when information is incomplete?
• Are urgent cases handled differently?
• What appeal or exception process exists?
• How are employees and prescribers supported?

Recommended Service Standards

Employers should evaluate:

• Timeliness
• Consistency
• Clinical governance
• Transparency
• Appeals
• Employee experience

The goal is appropriate administration, not automatic denial of expensive claims.

Specialty Pharmacy and Distribution Arrangements

Specialty medications may involve particular dispensing, distribution, storage or patient support requirements.

Employers should understand how these arrangements influence both cost and service.

Questions to Ask

• Which pharmacy networks are used?
• Are employees required to use particular providers?
• What financial terms apply?
• Are dispensing and distribution fees transparent?
• What patient support services are included?
• Are there relevant rebates or other compensation?
• How are conflicts of interest addressed?
• What happens if an employee requires an exception?

The Transparency Challenge

A lower administration fee does not necessarily mean lower total drug plan costs.

Different financial arrangements can affect the price ultimately borne by the employer.

Understanding the true cost of employee benefits requires examining relevant pharmacy-related compensation and charges, not just insurance premiums or administration fees.

Pharmacy Purchasing Collaboratives and Group Purchasing Opportunities

Some employers may have access to collaborative purchasing arrangements or other drug cost management programs.

These may involve negotiated pharmacy terms, purchasing arrangements or related services.

The structure and economics vary.

Potential Advantages

• Greater purchasing leverage
• More transparent financial arrangements
• Consistent pharmacy management
• Specialized expertise
• Better reporting

Questions to Evaluate

• What pricing mechanism applies?
• Which claims are eligible?
• What fees are charged?
• Are rebates or other payments retained or passed through?
• What services are included?
• Are there restrictions on pharmacy choice?
• How are financial benefits measured?
• What contractual commitments apply?

Avoid Assuming Savings

Purchasing arrangements should be evaluated using comparable net-cost assumptions.

A program offering attractive discounts may have additional fees or restrictions.

The employer should compare the complete financial and service arrangement.

Coordinate Private Drug Plans With Public Programs

Canada’s public prescription drug coverage is not uniform across provinces and territories.

Eligibility, covered medications, deductibles, coordination rules and reimbursement processes vary.

Some high-cost therapies may be eligible for public support under specific circumstances.

Others may not.

Coordination Questions

• Which public drug programs may be relevant?
• What eligibility requirements apply?
• How do private and public plans coordinate?
• Who helps employees navigate applications?
• Are there deadlines or documentation requirements?
• What happens when coverage changes?
• How are employer claims affected?

The Employer’s Role

Employers should support accurate coordination without placing unreasonable administrative burdens on employees.

Employees should receive clear guidance from appropriate insurers, administrators and program specialists.

Managing employee benefits across Canadian provinces requires particular attention to jurisdiction-specific rules.

Québec Considerations for Prescription Drug Benefits

Québec has a distinct prescription drug insurance framework.

Employers with Québec employees should not assume that drug plan provisions used elsewhere in Canada can be applied without modification.

Relevant considerations may include:

• Eligibility for private prescription drug insurance
• Minimum coverage requirements
• Coordination with the public plan
• Employee and dependant coverage
• Applicable financial participation rules
• Insurer and administrator obligations

The exact requirements depend on the circumstances and current law.

Employers should obtain qualified advice before changing drug coverage for Québec employees.

Understand High-Cost Drug Pooling in Canada

Pooling arrangements can influence how large claims affect group insurance pricing.

For fully insured benefits, an insurer may remove or treat qualifying claims differently when calculating experience-rated renewal costs.

However, the financial mechanics depend on the contract.

Questions Employers Should Ask

• What is the pooling threshold?
• Which claims qualify?
• How are pooled claims treated at renewal?
• What pooling charges apply?
• Are recurring claims treated differently?
• Are any medications excluded?
• How are threshold changes priced?
• What happens when the employer changes insurers?

Evaluating stop-loss and pooling arrangements should be part of every material specialty drug review.

Pooling Is Not the Same as Eliminating Cost

Pooling charges represent a cost of financial protection or risk sharing.

Claims may be excluded from certain experience calculations without becoming costless to the insurance system.

Employers should evaluate both the protection and its price.

EP3 and Canadian Industry Drug Pooling

The Canadian Life and Health Insurance Association’s industry drug pooling framework, commonly referred to as EP3, is relevant to certain eligible fully insured group drug arrangements.

However, employers should not assume that every group benefits plan, insurer or drug claim qualifies.

Eligibility and treatment depend on applicable industry rules and the specific insurance arrangement.

Important Distinctions

• Industry pooling is not identical to an employer’s contractual pooling provision.
• Not every high-cost claim is necessarily eligible.
• Recurring claim treatment can be subject to defined rules.
• ASO arrangements should not be assumed to receive the same protection as eligible fully insured plans.
• The insurer’s contract remains essential to understanding the employer’s financial position.

Questions for Your Broker

• Does our plan participate in an applicable industry pooling arrangement?
• Which claims are eligible?
• How does this affect our insurer’s pricing?
• What happens to recurring high-cost claims?
• How are pooling costs disclosed?
• What changes if we move to ASO or another insurer?

A broker should be able to explain the relationship between industry pooling, contractual pooling and renewal pricing.

ASO Plans: Managing Direct High-Cost Drug Exposure

Administrative Services Only arrangements can offer employers greater visibility into claims spending.

But they also create direct claims-funding exposure for the benefits the employer funds.

A specialty drug claim may affect the employer’s cash flow immediately.

ASO Risk Management Questions

• What is our maximum expected retained exposure?
• Which high-cost drug claims are eligible for stop-loss reimbursement?
• What attachment point applies?
• How quickly are reimbursements made?
• Are recurring therapies covered?
• Are there exclusions or limitations?
• What happens after termination?
• How should claims reserves be established?

Negotiating ASO contracts and stop-loss protection requires careful coordination between the administration agreement and the insurance policy.

Illustrative Specific Stop-Loss Scenario

Assume:

• One eligible annual drug claim costs $150,000.
• The employer has specific stop-loss protection with a $50,000 attachment point.
• The claim is fully eligible under the policy.
• There are no additional limitations.

Illustrative employer-retained amount:

$50,000

Illustrative stop-loss reimbursement:

$100,000

This is a simplified example.

Actual reimbursement depends on policy wording, eligibility, limits, timing and other provisions.

The employer also pays the cost of the stop-loss protection itself.

Evaluate Pooling Thresholds and Risk Retention

Higher pooling or stop-loss thresholds may reduce protection charges in some circumstances.

But they can also increase retained exposure.

Lower thresholds may offer greater protection at a higher cost.

Illustrative Threshold Comparison

Assume a qualifying individual claim costs $150,000.

The table illustrates a simplified specific stop-loss mechanism, assuming full eligibility and no other limits.

It does not represent every Canadian insurer pooling arrangement.

The employer must also consider the premium or charge associated with each threshold.

The Correct Decision

The optimal threshold depends on:

• Employer size
• Financial capacity
• Claims experience
• Protection pricing
• Risk tolerance
• Contract terms
• Cash-flow requirements

There is no universally optimal attachment point.

How Specialty Drug Claims Affect Group Insurance Renewals

High-cost claims may influence renewal pricing differently depending on the funding arrangement and pooling rules.

Employers should require a clear explanation of how the insurer treats material drug claims.

Questions to Ask During Renewal

• Which claims materially affected experience?
• Which claims were pooled?
• How were pooling charges calculated?
• What trend assumptions were applied?
• How were recurring therapies considered?
• Are future claims assumptions reasonable?
• What alternatives were evaluated?
• What financial impact would plan changes have?

Understanding your group insurance renewal report helps employers distinguish claims experience from other pricing components.

Avoid Misleading Savings Claims

Suppose an insurer initially proposes an 8% increase.

The broker negotiates a final increase of 5%.

That is a reduction of three percentage points relative to the proposal.

It is not a 3% reduction in current premiums.

Negotiating group insurance renewal costs should involve transparent explanations of both the final increase and the assumptions underlying it.

Build a Specialty Drug Financial Risk Model

Employers should evaluate expected costs and adverse scenarios.

The objective is to understand exposure rather than predict individual employees’ future health needs.

Illustrative Annual Drug Claims Model

Assume:

• Base annual drug claims: $1,200,000
• Other relevant costs and protection charges are modeled separately.
• The employer wants to assess additional gross specialty drug exposure.

All scenarios are hypothetical.

These are gross claim amounts, not necessarily the employer’s net financial exposure.

Add the Protection Layer

The employer should then model:

• Contractual pooling
• Stop-loss recoveries
• Public program coordination
• Other relevant offsets
• Protection charges
• Cash-flow timing

This produces a more meaningful net-cost forecast.

Compare Mitigation Strategies Using a Common Framework

Employers should not evaluate specialty drug management options solely on estimated savings.

A structured comparison should consider financial, clinical, operational and employee implications.

Recommended Strategy Comparison

A strong benefits advisor should provide evidence for each recommendation.

Protect Employee Access and Avoid Unintended Consequences

Specialty drug management decisions can materially affect employees and their families.

Employers should evaluate whether proposed changes create inappropriate barriers to treatment.

Key Principles

• Preserve access to clinically appropriate treatment within applicable plan and legal requirements.
• Provide clear information about coverage rules.
• Establish appropriate exception and appeal processes.
• Avoid unnecessary delays.
• Respect employee privacy.
• Consider the implications for employees with chronic or complex conditions.
• Evaluate the risk of shifting costs to employees.

Financial Optimization Is Not the Only Objective

A lower-cost drug program is not necessarily a better program if it creates substantial access problems.

The employer should consider the broader employee value of its benefits investment.

Integrating health and disability management can help employers coordinate relevant support services without treating medical claims simply as costs to eliminate.

Establish Privacy and Data Governance Standards

Drug claims data is sensitive health information.

Employers should receive reporting appropriate for plan management without unnecessary access to identifiable medical information.

Recommended Safeguards

• Aggregate reporting
• Appropriate suppression of small populations
• Role-based access
• Secure data transfer
• Clear contractual purposes
• Defined retention practices
• Vendor accountability
• Privacy review of new analytics or AI tools

The Small-Group Risk

Even an apparently anonymized report may create re-identification risks when the number of claimants is very small.

Employers should work with insurers and privacy specialists to establish suitable reporting thresholds and safeguards.

Evaluate Insurer and Pharmacy Administrator Performance

A specialty drug strategy depends on effective administration.

An attractive financial program may deliver poor value if employees experience delays, unclear requirements or repeated service problems.

Recommended Service Measures

The broker should maintain an escalation process for material issues.

What Your Benefits Broker Should Be Doing About Specialty Drug Costs

Specialty drug management should be an active part of the advisor’s responsibilities.

The broker should not simply present the insurer’s drug claims report and recommend accepting the renewal.

Expected Advisor Deliverables

What your benefits consultant should deliver each year should include proactive review of material drug plan risks and opportunities.

Questions to Ask Your Broker

• What is driving our specialty drug spending?
• Which claims are likely to recur?
• How much financial exposure are we retaining?
• Are our pooling terms competitive?
• Have we evaluated biosimilar opportunities?
• What compensation arrangements affect our net costs?
• Are there clinically appropriate alternatives?
• What should we change, and why?
• What results should we expect?
• How will we measure success?

The advisor should coordinate with appropriate clinical, actuarial, pharmacy, legal and privacy specialists.

The Specialty Drug Management Scorecard

A weighted scorecard can help employers evaluate their current strategy.

Recommended Evaluation Criteria

Rate each category from 1 to 5.

Weighted score:

Rating ÷ 5 × Category Weight

Illustrative Completed Assessment

The ratings are hypothetical.

The employer may have reasonable clinical and privacy safeguards but limited financial transparency, risk analysis and accountability.

A low score should trigger further evaluation rather than automatic coverage restrictions.

Build a Multiyear Specialty Drug Strategy

Specialty drug management should not be limited to annual renewal negotiations.

A multiyear approach helps employers assess persistent risks and plan changes responsibly.

Building a multiyear employee benefits strategy provides a framework for integrating financial sustainability, employee access and insurer performance.

Year One: Establish Visibility

Priorities:

• Review drug claims data
• Identify material cost drivers
• Evaluate pooling
• Assess pharmacy arrangements
• Review biosimilar and authorization policies
• Establish a financial baseline

Expected deliverable: Specialty drug performance assessment.

Year Two: Implement Targeted Improvements

Priorities:

• Implement appropriate plan-design changes
• Improve employee navigation
• Negotiate relevant commercial terms
• Monitor insurer service
• Track financial results

Expected deliverable: Documented implementation and performance measures.

Year Three: Optimize and Reassess

Priorities:

• Evaluate actual outcomes
• Review emerging treatments
• Reassess funding and protection
• Update pharmacy arrangements
• Revise the multiyear financial outlook

Expected deliverable: Updated specialty drug strategy and risk assessment.

Build the Executive Business Case for Specialty Drug Optimization

Material changes should be supported by a structured business case.

The business case should explain:

• The problem
• Current spending
• Claims drivers
• Available alternatives
• Expected financial impact
• Employee implications
• Risks
• Implementation requirements
• Measurement

Building a business case for employee benefits changes helps HR and Finance evaluate options consistently.

Recommended Executive Decision Framework

Avoid Unsupported ROI Claims

Projected gross drug savings may not translate directly into employer savings.

The financial model should account for:

• Pooling
• Stop-loss
• Protection charges
• Other offsets
• Implementation costs
• Insurer pricing
• Timing

A credible business case should distinguish expected savings from verified results.

Case Study: A Canadian Employer Reviews Rising Specialty Drug Costs

Illustrative employer scenario

Context

A Canadian employer has 1,200 employees.

Its annual group benefits premiums are approximately $4.8 million, using the illustrative $4,000-per-employee assumption.

Prescription drug claims have increased materially.

The employer is concerned about recurring high-cost therapies and future renewal increases.

The Assessment

The benefits advisor reviews:

• Aggregate drug claims
• High-cost exposure
• Pooling thresholds
• Pharmacy arrangements
• Biosimilar policies
• Insurer pricing assumptions
• Employee service issues

Illustrative Findings

The review identifies:

• Several recurring high-cost claims
• Unclear pooling cost reporting
• Potential biosimilar opportunities
• Pharmacy compensation requiring further clarification
• A need for improved employee navigation

The Recommended Approach

The employer adopts a coordinated strategy:

• Validate pooling terms
• Evaluate clinically appropriate biosimilar policies
• Review pharmacy arrangements
• Improve financial reporting
• Establish a multiyear drug claims forecast
• Monitor employee access and service

Illustrative Outcome

The organization gains greater visibility into drug costs and financial risk.

It also establishes a process for evaluating potential savings without assuming that every high-cost claim can or should be eliminated.

The case does not imply guaranteed savings or treatment outcomes.

The lesson:

The most effective specialty drug strategy combines financial protection, appropriate clinical management and transparent administration.

Common Mistakes Employers Make With Specialty Drug Claims

Treating All High-Cost Claims the Same

Different therapies have different clinical, financial and contractual characteristics.

Better approach: Evaluate the relevant claim categories and protection arrangements.

Assuming Pooling Eliminates Financial Risk

Pooling may affect experience rating but does not necessarily eliminate all costs.

Better approach: Review the actual contract.

Focusing Only on Gross Drug Prices

Gross claims may not reflect net employer costs.

Better approach: Evaluate applicable financial arrangements.

Introducing Restrictions Without Clinical Review

Coverage changes can affect access to necessary treatment.

Better approach: Use appropriate clinical and legal expertise.

Ignoring Recurring Claims

Some therapies may continue over multiple years.

Better approach: Develop multiyear scenarios.

Assuming Biosimilar Savings Are Automatic

Actual outcomes depend on eligibility, pricing, uptake and plan rules.

Better approach: Model realistic scenarios.

Overlooking Pharmacy Compensation

Relevant financial arrangements may not be transparent.

Better approach: Request clear disclosure.

Ignoring Employee Experience

Complex authorization processes can create frustration.

Better approach: Monitor access and service.

Waiting Until Renewal

Late analysis limits options.

Better approach: Review material drug trends throughout the year.

Failing to Hold the Broker Accountable

A claims report without recommendations provides limited strategic value.

Better approach: Require analysis, options and implementation.

Frequently Asked Questions About Specialty Drugs and High-Cost Claims

What are specialty drugs in group benefits?

Specialty drugs are medications classified as specialized under an insurer or pharmacy management framework, often involving complex treatment, handling, administration or high costs.

Why are specialty drugs expensive?

Costs may reflect complex development and manufacturing, specialized treatment requirements, pricing arrangements and other factors. The reasons vary by medication.

How do high-cost drug claims affect group insurance renewals?

The effect depends on claims experience, insurer pricing, pooling arrangements and contract terms. Not every high-cost claim affects renewal pricing in the same way.

What is high-cost drug pooling?

Pooling is an arrangement that changes how qualifying large claims are treated for specified insurance pricing or risk-sharing purposes.

Does pooling cover every expensive drug?

No. Eligibility depends on the applicable contract, thresholds, definitions and exclusions.

What is EP3 in Canadian group benefits?

EP3 refers to a Canadian industry drug pooling framework relevant to certain eligible fully insured group drug arrangements. It should not be assumed to apply to every plan or claim.

What is a biosimilar drug?

A biosimilar is a biologic drug authorized as highly similar to a reference biologic under applicable regulatory requirements.

Can biosimilars reduce group benefits costs?

They may reduce costs for eligible therapies, but actual financial results depend on pricing, utilization, plan design and other arrangements.

What is prior authorization for specialty drugs?

Prior authorization is a process used to determine whether a medication meets specified coverage criteria before reimbursement approval.

How can employers reduce specialty drug costs?

Potential approaches include appropriate biosimilar policies, prior authorization, pharmacy management, purchasing arrangements, public program coordination, contract negotiation and risk protection.

How should ASO employers manage high-cost drug claims?

They should evaluate claims exposure, stop-loss eligibility, attachment points, cash flow, recurring claims and contractual protections.

Should employers impose annual drug maximums?

Not automatically. Drug maximums can create significant employee access issues and should be evaluated carefully against clinical, contractual and legal considerations.

What should a benefits broker do about specialty drug claims?

The broker should analyze costs, explain risk protection, evaluate relevant alternatives, negotiate commercial terms and recommend appropriate actions.

Strategic Takeaways for HR and Finance Leaders

• Understand specialty drug exposure. High-cost claims can materially affect plan economics.
• Separate frequency from severity. Identify the actual cost drivers.
• Evaluate recurring claims. Consider multiyear exposure.
• Use reliable claims analytics. Avoid conclusions from incomplete data.
• Review plan design carefully. Balance cost and access.
• Evaluate biosimilars. Consider clinically appropriate opportunities.
• Monitor prior authorization. Protect timely treatment access.
• Review pharmacy arrangements. Understand relevant financial incentives.
• Assess purchasing opportunities. Compare net costs.
• Coordinate public coverage. Apply jurisdiction-specific rules.
• Understand Québec requirements. Avoid assuming national uniformity.
• Review pooling. Know what protection applies.
• Clarify EP3 eligibility. Industry pooling is not universal.
• Evaluate ASO stop-loss. Understand retained exposure.
• Model thresholds. Compare protection costs and risk.
• Challenge renewal assumptions. Demand transparent pricing.
• Build financial scenarios. Distinguish gross from net costs.
• Protect employees. Avoid inappropriate access barriers.
• Maintain privacy. Use appropriate aggregate reporting.
• Measure insurer service. Administration matters.
• Hold your broker accountable. Expect proactive advice.
• Plan beyond renewal. Establish a multiyear strategy.

Employer Action Checklist: Managing Specialty Drugs and High-Cost Claims

Use this checklist to evaluate your current drug benefits strategy.

Understand Current Spending

• [ ] Review drug claims. Identify material trends.
• [ ] Analyze specialty exposure. Understand high-cost categories.
• [ ] Evaluate recurring claims. Assess persistence.
• [ ] Normalize the data. Consider covered population.
• [ ] Establish a baseline. Document current costs.

Evaluate Financial Protection

• [ ] Review pooling thresholds. Confirm applicable terms.
• [ ] Clarify EP3 eligibility. Understand industry pooling where relevant.
• [ ] Assess stop-loss. Identify retained risk.
• [ ] Review exclusions. Understand coverage limitations.
• [ ] Model adverse scenarios. Evaluate financial exposure.
• [ ] Assess cash flow. Consider ASO funding requirements.

Evaluate Cost Management

• [ ] Review biosimilar policies. Assess appropriate opportunities.
• [ ] Evaluate prior authorization. Review clinical and service standards.
• [ ] Assess pharmacy arrangements. Understand net costs.
• [ ] Review purchasing programs. Compare commercial terms.
• [ ] Coordinate public programs. Confirm applicable rules.
• [ ] Evaluate plan design. Consider employee implications.

Establish Accountability

• [ ] Request broker recommendations. Require specific analysis.
• [ ] Review insurer performance. Monitor service.
• [ ] Protect privacy. Establish reporting safeguards.
• [ ] Prepare a business case. Compare alternatives.
• [ ] Assign ownership. Establish implementation responsibility.
• [ ] Track outcomes. Measure financial and employee impacts.
• [ ] Review quarterly. Monitor emerging trends.

Your First 90 Days

Complex changes may require longer timelines, particularly when insurer contracts, clinical policies or employee communications are involved.

Final Thoughts

Specialty drugs are changing how Canadian employers need to manage their prescription drug benefits.

High-cost therapies can create significant financial exposure.

But they can also provide important treatment options for employees and their families.

The challenge is not to choose between affordability and access.

It is to manage both responsibly.

That requires better claims analytics, clearer pharmacy economics, appropriate clinical management, effective pooling and stop-loss protection, and a more sophisticated approach to insurer negotiations.

It also requires stronger expectations of benefits advisors.

A high-performing consultant should help employers understand the risks, evaluate the options and make informed decisions before costs become a renewal surprise.

For HR leaders, the priority is preserving meaningful employee coverage and a positive benefits experience.

For Finance leaders, it is understanding financial exposure and improving long-term sustainability.

For both, the opportunity is to turn specialty drug management from a reactive claims problem into a disciplined strategic process.

The strongest specialty drug strategy isn’t the one that restricts the most treatments. It’s the one that protects access to appropriate care while making every available financial, clinical and contractual mechanism work more effectively.